Pharvaris NV is seeking to improve upon the standard-of-care for both treatment and prevention of hereditary angioedema (HAE) with its oral bradykinin B2 receptor antagonist deucrictibant, announcing on 5 September that it expects to launch a pivotal Phase III study by year’s end for a daily, extended-release formulation of its drug for prophylaxis. An immediate-release formulation is already in Phase III for treatment of HAE attacks.
Pharvaris Seeks To Offer New Standard Of Care In HAE
A Phase III trial with oral deucrictibant is underway for treatment of acute hereditary angioedema attacks, while the Swiss firm will begin a Phase III trial in prophylaxis later this year.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.